Signature gene expression profile of triclosan-resistant Escherichia coli

J Antimicrob Chemother. 2010 Jun;65(6):1171-7. doi: 10.1093/jac/dkq114. Epub 2010 Apr 21.

Abstract

Objectives: To gain further insight into the defence mechanisms against triclosan in a mutant derived from an Escherichia coli strain carrying the triclosan-resistant target enzyme, FabI(G93V).

Methods: An E. coli imp4231 FabI(G93V) strain was constructed by replacing intact fabI with a linear DNA cassette, fabI(G93V)-CmR, that contains a single mutation, GGT to GTT, at codon 93 of fabI(G93V) and a chloramphenicol resistance gene (CmR) as a marker for the mutant allele by a Red-mediated recombination system. Using this E. coli imp4231 FabI(G93V) strain, nitrosoguanidine (NTG) mutagenesis was performed to generate E. coli IFNs [imp4231 FabI(G93V) treated with NTG] displaying higher MICs of triclosan than its parent strain. The genes overexpressed in E. coli IFN4 were identified by DNA microarray analysis.

Results: An E. coli imp4231 FabI(G93V) strain displays approximately 400-fold increased MICs of triclosan (MIC approximately 8 mg/L) compared with the parent strain (MIC approximately 0.02 mg/L). Furthermore, E. coli IFN4 has the highest MIC of triclosan (MIC approximately 80 mg/L). DNA microarray analysis of E. coli IFN4 shows that many genes involved in the biosynthesis of membrane proteins, including transporters, reductases/dehydrogenases and stress response regulators, were highly expressed in the mutant.

Conclusions: These results strongly indicate that E. coli IFN cells might protect themselves from triclosan by activating various defence mechanisms, such as (i) changing efflux activities; (ii) capturing the triclosan; and (iii) increasing the expression of important regulators or metabolic enzymes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution / genetics
  • Anti-Infective Agents, Local / pharmacology*
  • Drug Resistance, Bacterial*
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / genetics
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / metabolism
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics*
  • Escherichia coli Proteins / genetics
  • Escherichia coli Proteins / metabolism
  • Fatty Acid Synthase, Type II
  • Gene Expression Profiling*
  • Genes, Bacterial
  • Microbial Sensitivity Tests
  • Mutagenesis, Site-Directed
  • Mutagens / pharmacology
  • Mutant Proteins / genetics
  • Mutant Proteins / metabolism
  • Nitrosoguanidines / pharmacology
  • Oligonucleotide Array Sequence Analysis
  • Recombination, Genetic
  • Triclosan / pharmacology*

Substances

  • Anti-Infective Agents, Local
  • Escherichia coli Proteins
  • Mutagens
  • Mutant Proteins
  • Nitrosoguanidines
  • Triclosan
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)
  • fabI protein, E coli
  • Fatty Acid Synthase, Type II